| MITO CHONDRIAL D IS E A S E S , THEIR INHERITAN CE AND HE TEROPL A S MY
The primary role of mitochondria is aerobic respiration, that is, oxidative phosphorylation (OXPHOS) and the production of cellular energy in the form of adenosine triphosphate (ATP). MtDNA encodes 37 genes (13 genes for polypeptides, 22 genes for transfer RNAs, and two genes for ribosomal RNAs) that are crucial for production of cellular energy and programmed cell death (apoptosis). 3 Mitochondrial disorders or diseases attributable to defects in oxidative phosphorylation are mostly severe disorders and affect at least one in 8000 individuals. 4 Such conditions can be fatal or cause chronic morbidity and usually affect the most energy-demanding tissues such as the central nervous system, heart and skeletal muscles, liver, and kidney. 5 Mitochondrial diseases can be caused by genetic alterations of nuclear-or mitochondrial-encoded genes involved in the synthesis of ATP. While disorders resulting from nuclear DNA mutations follow a Mendelian pattern of autosomal recessive, autosomal dominant or X-linked inheritance, the inheritance patterns of conditions arising from mtDNA defects are quite different. First, affected individuals are usually heteroplasmic, that is, there is a mixture of normal and mutant mtDNA, the levels of which can differ among tissues. If the mutant load, that is, the ratio of mutant to normal mtDNA, exceeds a tissue-and individual-specific threshold, clinical features become evident, although exact genotype-phenotype correlations usually vary even within families. 5 Second, unlike the nuclear genome, mtDNA is transmitted maternally. 6 This is due to the significantly higher number of mtDNA molecules in a mature oocyte (200 000-300 000 copies) compared to the sperm (approximately 100 mtDNA copies). 7, 8 In addition, sperm mitochondria that enter via fertilization are eliminated specifically during early embryo development. 9 Diseases caused by mtDNA mutations were first described in 1988. [10] [11] [12] Since then, over 150 mutations (including 100 deletions and approximately 50 point mutations) associated with human diseases have been identified (see for review 13 ). In addition, mtDNA mutations are also increasingly implicated in a range of socially recognizable conditions, including Alzheimer's, Parkinson's, and
Huntington's diseases, obesity, diabetes, and cancer. [14] [15] [16] Interest in the study of these conditions has grown enormously due to the large number of patients diagnosed with these disorders and to the fact that they appear throughout life, from newborns to adults of all ages. In summary, defects in mtDNA are clearly associated with a wide range of human diseases for which, at present, there is little or no available treatment. Given the fact that many of these disorders are dependent on the heteroplasmic state of the mtDNA and associated threshold effects, it is difficult to provide accurate genetic counseling based on preimplantation or prenatal genetic diagnoses.
Affected families have been seeking and awaiting promising-assisted reproductive options, which could prevent transmission of mtDNA mutation to their children. Therefore, there is an urgent need to develop new therapeutic approaches that could prevent the transmission of mtDNA mutations from the mother to the child. Table 1 . In this section, we summarize the technical concepts, accumulated knowledge of CT, GVT, PNT, and PBT.
Cytoplasmic transfer was initially introduced as a procedure to supplement patient eggs with the donor cytoplasm. The rationale was to improve viability and developmental competence of compromised oocytes, where the underlying cause was determined as "ooplasmic deficiency." This procedure was offered to patients who had undergone repeated in vitro fertilization (IVF) cycles with implantation failure due to poor embryo development. Attempts to introduce sufficient amounts of donor cytoplasm by electrofusion were not successful due to low fertilization rates (23%), pronuclear anomalies, and poor embryo development. 27 However, CT as an extension of intracytoplasmic sperm injection (ICSI) involving coinjection of a small amount of donor cytoplasm with sperm has been more successful. [27] [28] [29] This approach was used to treat patients in several fertility clinics, and purportedly improved IVF outcomes and resulted in live birth. 28, 30 Patients involved in these procedures were not suspected of having any mtDNA mutations, and only small volumes (1%-5%) of donor cytoplasm were injected. However, while donor cytoplasmic mtDNA was detected in small amounts in 6 of 13 embryos studied and in 2 of 4 fetal cord blood samples. 31 
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An alternative strategy to CT is to transfer the nuclear DNA from a mother with mtDNA disease to an enucleated oocyte containing normal mtDNA from a healthy female. Results of experiments conducted with mice suggest that it is technically feasible to transfer DNA between immature oocytes, in which nuclear DNA is enclosed in a clearly visible germinal vesicle. 33 The GV surrounded by a small amount of cytoplasm and a membrane (karyoplast) can be removed using a micropipette and placed into the perivitelline space of an enucleated GV oocyte (cytoplast). Fusion of the karyoplast and cytoplast is generally induced by electroporation. If this approach was applied to human oocytes, efficacy would be limited by the poor developmental competence of oocytes produced after in vitro maturation (IVM) of GV-intact oocytes. Moreover, GV oocytes have polarized cyto-architecture, with the mitochondria concentrated in the perinuclear space, possibly due to increased energy requirements of the nucleus. 34 Transplant of GVs would inevitably result in significant amounts of patient mtDNA in the donor cytoplasm. It is further possible that, due to its initial proximity to the nucleus, mutant mtDNA would be preferentially replicated in the reconstructed embryo.
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Pronuclear transfer is essentially the same procedure, except for the nuclear material being removed after fertilization. The 2PNs of a patient's zygote enclosed in the karyoplast is removed and transplanted to an enucleated comparable stage of zygote cytoplast, derived from donors containing healthy mitochondria. This technique has also been used in mice with considerable success, as determined by the birth of live offspring. [36] [37] [38] Similar to GVT, reconstructed embryos contained a significant portion of karyoplast mtDNA where the carryover mtDNA was detected in the pups at a range of 19%−35%. Derived fetuses were all heteroplasmic and heteroplasmy levels varied with tissue type, from 6% in the lung to 69% in the heart. 36, 38 Recent PNT study with mouse also demonstrated significantly high level of 23.7% ± 11.1% on average heteroplasmy in F1 pups. 39 At the zygote-stage, mitochondria are accumulated as a conglomeration around the pronuclei. 40, 41 Thus, the PNT procedure may result in cotransfer of mitochondria with abnormal mtDNA, even if isolated with only 2PN, encapsulated in small karyoplasts.
However, PNT in humans has shown different outcomes than that in mice. Craven et al 42 reported a study using PNT with abnormally fertilized (unipronuclear or tripronuclear) human zygotes in 2010. Of the 36 reconstructed zygotes, three embryos (8.3%) developed to the blastocyst stage, and the average mtDNA carryover was 2% with the proportion of mtDNA genotype variation among blastomeres.
Thus, the blastocyst development of human PNT with abnormally fertilized embryos was extremely inefficient. Further study utilizing normally fertilized human embryos along with the adjustment for timing to manipulation, that is, ePNT, exhibited improved blastocyst development. 43 Furthermore, heteroplasmy can be lowered by the omission of sucrose from the manipulation media and by utilizing the vitrifying donor cytoplast. 43 However, blastocyst formation of the ePNT embryos with vitrifying cytoplast was inferior to control autologous PNT embryos. Furthermore, there was inconsistency in significant portion of embryos, even with optimized ePNT embryos (21%) still exhibiting >5% heteroplasmy, whereas the initial attempts of PNT with abnormally fertilized embryos showed an average of 2% heteroplasmy. The author discussed that this could be attributed to technical problems, such as leakage from the cytoplast or inadequate shearing of cytoplasm form kyaroplast and such factors could be taken into account when selecting embryos for use in clinical treatment. 43 However, these inconsistencies have led to concerns that human PNT may also result in significant heteroplasmy in their offspring, sufficient for the disease to manifest, similar to that seen in mice PNT. 36 Although there are some concerns, PNT has been considered to be a potential MRT technique in the United Kingdom and clinical trial is now being conducted.
Polar body nuclear transfer has also been proposed as a potential MRT in mice. 39 Mammalian oocytes undergoing meiotic division sequentially extrude two sets of nuclear genomes as small polar bodies (PBs), that is, first and second polar body (PB1 and PB2). In the late 90 s, the developmental potential of transplanted PB1 and PB2, into an appropriate oocyte or zygote cytoplasm, which resulted in live birth, was investigated in mice. 44, 45 In 2014, Wang et al expanded PBT as a potential MRT and compared both PB1 transfer (PB1T) and PB2 transfer (PB2T) with other MRT techniques, such as MST and PNT. 39 PBT, especially PB1T, demonstrated more favorable outcomes, where carryover of mtDNA from nuclear material was less compared to the other alternative strategies, not only in the F1 but also in the F2 pups. A recent study has also demonstrated that PB1T in humans and resulted in chromosomally normal ESC lines, however, the developmental potential of the reconstructed oocytes was lower than controls. 46 The results suggested that metaphase II-arrested human oocytes may have limited potential to properly assemble a normal bipolar spindle, following PB1T, compared to mice.
The above results supported the notion that rescue of PB1, via introduction into the donor cytoplasm, may offer an MRT for mtDNA diseases. However, unsolved questions remain in PBT, such as the errors in segregation of chromosomes at meiosis, the best timing for transfer (since mammalian PBs show short lifetime due to apoptotic pressures that lead to DNA fragmentation or degradation) and a precise distinction from maternal pronucleus, in the case of PB2T.
Importantly, the genetic composition of PB1 and PB2 is not identical to MII chromosomes and the female pronucleus because of meiotic recombination. 47 
| RE S E ARCH MILE S TONE OF MATERNAL S PINDLE TR AN S FER (MS T )
Maternal spindle transfer (MST), also referred to as spindle-chromosomal complex transfer (ST), was first reported as a novel revolutionary approach to avoid transmission of inherited mitochondrial disease in 2009. 48 MST takes place in mature metaphase II (MII) oocytes where MII spindle-chromosomal complex is isolated as membrane-enclosed karyoplast and is transferred into an enucleated (nuclear material free) cytoplast from healthy donor MII oocyte ( Figure 1) . 48 Since 2009, MST has been thoroughly examined not only in primates, but also in humans carrying pathogenic mutations. Genetic analyses of both nuclear DNA and mtDNA revealed the proof of concept that there was successful replacement of cytoplasmic material from the cytoplast donor, whereas the maintenance of nuclear genetic inheritance of the original female and male was retained. The carryover of mtDNA from spindle donor (ie, degree of heteroplasmy), both in MST infants and in derived ESC lines, exhibited undetectable or below 3% heteroplasmy. 48 In contrast, MST in mice exhibited different outcomes that on average 5.5% ± 1.4% het- Based on the results discussed in this review, brief exposure of oocytes to these reagents appears to be nondetrimental. On the other hand, random genetic drift or segregation can also be causal for unexpected heteroplasmy change during early embryogenesis, as described above. 22 heteroplasmy. 22 A recent study has also demonstrated that isolated human PGCs in vivo exhibit a profound reduction in mtDNA content, and rare variants subsequently reach higher heteroplasmy levels in late PGCs, consistent with the observed genetic bottleneck. 64 Even though mtDNA carryover in MST oocytes is as low as 1%, heteroplasmy may be altered when mtDNA goes through the female germ line. Lee et al, 22 explored heteroplasmy in oocytes, where they found that female MST monkeys, having two oocytes (a twelfth from each fetus), exhibited a substantial degree of mtDNA carryover (16.2% and 14.1%, respectively), albeit both the somatic lineages and majority of the eggs displayed low or undetectable mtDNA heteroplasmy.
Although it was not drastic shift, slightly increased heteroplasmy (on average 7.1% ± 6.8%) has been observed in F2 pups while the original heteroplasmy in F1 pups was 5.5% ± 1.4% in mice. 50 Thus, there is a possibility of disease manifestation in future generations of MRT, which will probably become evident after two generations. As noted above, limiting MRT to male embryos takes away the fear related to the transmission of mtDNA diseases as well as unexpected side effects of MRT to future generations, since mtDNA inheritance is exclusively maternal. In this regard, the institute of Medicine of the National Academies of Science, Engineering and Medicine published a report (referred to as "NAS report") addressing the border concerns of MRT, and the report recommended to move cautiously, limiting only to the transfer of male embryos, in future clinical trials.
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However, this solution may raise some ethical questions regarding the fate of female embryos and the consequences of;"require parents to engage in sex selection". 66 In contrast to United States, the limitation to male embryos was rejected in the United Kingdom. Unfortunately, it is unlikely that the first case of MRT will be offered such a benefit. The current legislation and regulation for human embryo research vary considerably in each country; however, it is essential to have an appropriate foresight to establish safety and efficacy requirements and guide government-funded clinical trials for future application of all MRT procedures.
| WIDER IMPLI C ATI ON OF MRT TECHNI Q U E
In modern ART, maternal aging is the main cause of impaired outcomes. It has been reported that the 4977-bp deletion in mtDNA is commonly observed in unfertilized oocytes 68 or in oocytes from advanced maternal age. 69 Some point mutations and deletions in the mtDNA of oocytes increase with aging. 70 Either a significant loss of mtDNA or accumulation of defective mtDNA will affect oxidative phosphorylation and will negatively impact proper completion of meiosis, fertilization, and early preimplantation embryo development. 71 Embryo aneuploidy increases with maternal age as a result of errors in meiotic division I or II. 72, 73 In addition, mitotic error during early embryonic cleavage division may occur and result in mosaic blastocyst formation. 74 Significant portion of chromosomally normal diploid embryos still fail to implant in preimplantation genetic testing for aneuploidy (PGT-A) cycles and implantation rate decreases with maternal age. 75 Furthermore, almost 10% of implanted chromosomally normal embryos still result in miscarriage. This might also be attributed to cytoplasmic deficiency, and thus the cytoplasmic factor may have an impact on the initiation of pregnancy, as well as on postimplantation development.
Mitochondrial replacement therapy could be considered ART technique to solve cytoplasmic defects due to aging. As described above, one of the MRT techniques, CT, was initially developed to improve viability and developmental competence of compromised oocytes, resulting from aging. 28 Hence, CT has already been applied to humans and has demonstrated improved ART outcomes. 27, 30 However, this procedure has been banned by the 79 It has been demonstrated that spindles in suboptimally cryopreserved oocytes can be rescued by transplanting into fresh cytoplasts using MST in primates. 51 It is known that 
| CON CLUS IVE REMARK S
In summary, a new assisted reproductive technique involving MRT, described here, could potentially prevent the transmission of mtDNA diseases and could be a new improvisation for modern ART. Since there are no fundamental cures for mitochondrial diseases so far, MRT could potentially provide significant health and social benefits to those affected families with the elimination of the risk of disease transmission, and thus, enable them to live a healthy life, free from progressive and lethal disorders. Meanwhile, a powerful genome editing tool called CRISPR has been applied to edit defective genes in human gametes/embryos or to investigate and understand human embryology. 81 Although mitochondrial diseases, caused by mutation in nuclear encoded genes, cannot be offered MRT, genome editing may offer curative treatment options for such patients in future.
With the advent of newer and safer technologies, a shift in the worldwide consensus on prohibition of gene modification in human gametes or embryos, toward allowing the correction of altered genes in gametes or in early embryos, is a possibility in the near future. Thus, the new era of ART, where cures can be provided in gametes or early zygotes, is underway. Authors would like to emphasize that recent fundamental discoveries were successfully made from indispensable and valuable quality human oocytes, donated for research. According to Jose Cibelli, "The need for human eggs for research is back. It seems like it never left the stage after all.". 82 We should realize that monkey is not a big mouse, as well as humans are not the exact counter parts of non-human primates.
Therefore, further research using human gametes/zygotes, could be warranted to ensure the safety and efficacy of MRT.
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